Midostaurin (Rydapt) has been approved in order to treat adult patients with AML. As a multi-targeted protein kinase inhibitor, it blocks the several protein kinase enzymes that are involved with cell growth, and prevent the growth of the leukaemia cells. A bit more specifically, midostaurin 25 mg capsules inhibit the signals from the FLT3 receptor, stopping the cell cycle as well as promoting the death of the leukaemia cells that have the FMS-like tyrosine 3 mutation.
Who receives midostaurin?
It is recommended for adult patients who are with newly-diagnosed acute myeloid leukemia who have the FMS-like tyrosine 3 mutation.
This drug is also recommended in order to treat some patients with an absolutely different haematological condition named advanced systemic mastocytosis.
How is midostaurin administered?
It is mostly recommended to be used in along with other chemotherapies. It is approved for use together with daunorubicin and cytarabine as induction treatment for AML adult patients with newly diagnosed AML and a FMS-like tyrosine 3 mutation. In acute myeloid leukemia patients with a complete response, this medication is consumed with high-dose cytarabine in the form of consolidation chemotherapy, and can be used as a single agent for the maintenance therapy.
- Consume midostaurin 25 mg at the same time each day to help you in order to remember when you have to take your dose.
- Midostaurin is consumed with food.
- It is taken twice daily at about 12-hour intervals.
- Capsules are swallowed whole with water. Do not crush, open, or chew them to make sure you get the full dose and any unpleasant taste of the capsule content should be avoided.
- In case consumed with chemotherapy, you must follow the words of your healthcare provider.
- Nausea
- Vomiting
- Diarrhoea
- Headache
- Fever
- Nose bleeds
- Bleeding gums
- Redness
- Peeling of the skin
- Raised temperature (over 38°C/100.4°F)
- Unexpected bruising/bleeding
- Eye pain
- Dry or watery eyes
- Feeling very tired
- Short of breath






